- Home
- IBG vs COEP Comparison
IBG vs COEP Comparison
Compare IBG & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBG | COEP |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 100.4M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | IBG | COEP |
|---|---|---|
| Price | $2.52 | $15.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 276.6K | 74.3K |
| Earning Date | 05-12-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,931,243.00 | $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.48 | $2.31 |
| 52 Week High | $9.85 | $21.41 |
Technical Indicators
Market Signals| Indicator | IBG | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 47.72 |
| Support Level | $2.19 | $15.40 |
| Resistance Level | $2.99 | $16.80 |
| Average True Range (ATR) | 0.36 | 1.57 |
| MACD | 0.07 | -0.11 |
| Stochastic Oscillator | 56.08 | 20.64 |
Price Performance
Historical ComparisonAbout IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.